GreenMethyl Presents Longevity AI Initiative at the 26th Japanese Society of Anti-Aging Medicine Annual Meeting

GreenMethyl Co., Ltd. presented on its Longevity AI initiative at the 26th Japanese Society of Anti-Aging Medicine Annual Meeting, held from Friday, June 26 to Sunday, June 28, 2026, at Pacifico Yokohama North.

The 26th Japanese Society of Anti-Aging Medicine Annual Meeting is an academic conference hosted by the Japan Society of Anti-Aging Medicine, with the theme: 'Anti-Aging in the Anthropocene: Integrated Medicine through Diet, Exercise, Sleep, and Aesthetics'.

The presentation was part of the 'Presidential Symposium 4: AI Technology' session. According to the official program, the presentation title was 'Medical AI for Blood Nutrient Analysis Reports and Treatment Roadmap Generation', delivered by Ryota Kobayashi of GreenMethyl Co., Ltd.

The presentation introduced a conceptual framework for Longevity AI that goes beyond disease management and test result visualization. It emphasized integrating data such as blood tests, medical interviews, symptoms, lifestyle context, and health goals to support physicians' clinical judgment, patient communication, and shared decision-making.

◾️ Background: Longevity as an Integrated Domain Connecting Physical, Functional, Environmental, Cognitive, and Behavioral Data

In the field of Longevity, diverse physiological data—including blood tests, nutritional status, inflammation, metabolism, sleep, physical activity, symptoms, and lifestyle habits—are increasingly being utilized.

These data serve as a critical foundation for assessing health status, planning interventions, and monitoring progress. However, extending healthspan requires more than just biomarkers and lab values. It necessitates a holistic understanding of daily functioning, decision-making, living environment, and the sustainability of behavioral changes.

The World Health Organization (WHO) defines Healthy Ageing as the process of developing and maintaining the functional ability that enables well-being in older age. Functional ability is understood as a combination of intrinsic capacity, environmental characteristics, and the interaction between the two.

From this perspective, Longevity AI must extend beyond mere test data analysis. It should connect physiological data with personal cognition, life context, decision-making, and behavioral continuity to support real-world functional ability.

◾️ Cognitive Science Perspectives Essential for AI-Supported Behavior Change

Health behaviors are not determined solely by knowledge or willpower.

Behavior change research identifies three core components: individual capability, environmental opportunity, and motivation. The COM-B model explicitly outlines these as Capability, Opportunity, and Motivation—the essential elements for behavior to occur.

Reference: https://link.springer.com/article/10.1186/1748-5908-6-42

Additionally, the Health Belief Model identifies cognitive factors influencing health behavior: perceived susceptibility, perceived severity, perceived benefits of action, perceived barriers, self-efficacy, and cues to action.

Reference: https://www.ncbi.nlm.nih.gov/books/NBK606120/

These frameworks demonstrate that merely presenting physiological data is insufficient for Longevity support. Beyond reporting test results and lifestyle issues, it is essential to understand how individuals interpret information, perceive barriers, assess feasibility, and identify environmental conditions that support sustained behavior.

GreenMethyl focuses on the feasibility of implementing Longevity AI that integrates cognitive science with biochemistry. Health behaviors are not determined by knowledge or willpower alone. Behavior change requires the interplay of capability, opportunity, and motivation.

◾️ Longevity AI Concept: Integrating Cognitive and Biochemical Data

GreenMethyl's Longevity AI concept envisions integrating not only biochemical data—such as blood tests and nutritional analysis—but also cognitive science data, including life context, health goals, behavioral history, self-efficacy, stress perception, and decision-making processes.

This integration aims to build an AI platform that holistically manages test data interpretation, lifestyle assessment, intervention prioritization, patient communication, shared decision-making, and ongoing support.

The AI in this concept does not replace clinical judgment. Under the premise that diagnosis, treatment planning, and medical interventions remain the responsibility of physicians and healthcare professionals, AI serves as a supportive infrastructure for information organization, explanation assistance, decision support, and progress tracking.

In clinical settings, physicians are required to synthesize multiple data points—lab results, symptoms, lifestyle factors, and personal health goals—within limited consultation time and present them in a way patients can understand. Longevity AI is designed to assist in this complex information processing and support physician-patient consensus building.

◾️ Future Directions

Going forward, GreenMethyl will expand cross-sector collaborations with healthcare providers, research institutions, corporations, and experts across anti-aging medicine, preventive care, nutritional therapy, behavior change support, medical AI, and human capital management.

This initiative is not intended to replace diagnosis or treatment by AI. Instead, it aims to serve as an information infrastructure that supports clinical decision-making by organizing test data, life context, and cognitive science data to enable better communication, shared decision-making, and sustained support.

Through research and implementation of Longevity AI that integrates cognitive science and biochemistry, GreenMethyl aims to enhance healthspan, performance, and decision-making quality for individuals and organizations.

◾️ Presentation Overview

Conference: 26th Japanese Society of Anti-Aging Medicine Annual Meeting Dates: June 26 (Fri) – June 28 (Sun), 2026 Venue: Pacifico Yokohama North Organizer: Japan Society of Anti-Aging Medicine Theme: 'Anti-Aging in the Anthropocene: Integrated Medicine through Diet, Exercise, Sleep, and Aesthetics' Session: Presidential Symposium 4: AI Technology Presentation Title: Medical AI for Blood Nutrient Analysis Reports and Treatment Roadmap Generation Presenter: Ryota Kobayashi (GreenMethyl Co., Ltd.)

*The Longevity AI concept described in this release is not intended to replace diagnosis, treatment planning, or medical interventions by physicians or healthcare professionals. It is designed as a supportive infrastructure for information organization, explanation support, decision support, consensus building, and progress monitoring in clinical settings.

Inquiries Regarding This Release

Contact Form: https://greenmethyl.com/contact/

Company Information

Company Name: GreenMethyl Co., Ltd. Address: 1-378 Sakuragicho, Omiya-ku, Saitama City, Saitama Prefecture 330-0854 Representative: Ryota Kobayashi Founded: February 1, 2021 Capital: ¥87,306,316 (including capital reserves) Business Activities: Development and operation of healthcare services leveraging health data and medical technology, including Medi Tec Hub, MTH Assistant, and Health Focus Method

Main Services: Medi Tec Hub, MTH Assistant, Health Focus Me